Genesis Pharma S.A.

An impressive series of developments in biology have triggered the most recent results in the area of research for the decoding of the human genome, promising pharmaceutical scientists new therapies such as personalized medicines. Until now, scientists have managed to unravel the meaning and the function of approximately 10% of the human genes, whilst within the next decade it is believed that a real "boom" of information and data will take place that will materialize this hope. The use of more live organisms - plant cells, animal cells and viruses - will help to scale up the production of medicines for human use. This progress combined with the development of information on health through the internet, telemedicine, and the potential of buying medicines through the internet, will mark a significant change in health. Foreseeing this potential in biotechnology GENESIS Pharma was incorporated with the mission to market and distribute specialized biotechnology-derived products for chronic diseases in Greece and SE Europe. For biotechnology in general and the company more specifically, the CEO of GENESIS Pharma agreed to be interview by "Imerisia".

Primarily, let's clarify that there are four primal categories of Medicaid where biotechnology is currently used: medicines, vaccines, diagnostics and gene therapy.

The human body, from its nature, produces literally thousands of proteins, which fight diseases and modulate everything, from the blood sugar levels to the human evolution. Biotechnology-derived medicines that have been approved for use are proteins that help the human body fight infections or are programmed to perform specific functions. For the time being, the only FDA approved biotechnology-derived products are for the treatment of anemia, cystic fibrosis, hemophilia, leukemia, hepatitis and various cancers.

Biotechnology contributes to human health through the development of new vaccines that help the human body recognize and fight diseases. The traditional vaccines use weak or dead forms of a virus or a bacterium in order to place the "anti-virus", i.e. proteins, to the surface of the viruses which the human immune system uses in order to recognize the pathogenicity. Following that, the human body produces antibodies that develop resistance to the disease. A biotech vaccine is not comprised of the real microbe but from the "anti-virus". By isolating the antigens and their laboratory reproduction, it is feasible to develop new vaccines that cannot infect the virus itself.

Biotechnology diagnostics are used in tracing various diseases and genetic conditions. Pregnancy tests performed at home, for example, are biotechnology diagnostics; the same is the new blood test for the measurement of LDL or bad cholesterol in the blood.

A much promising technology that uses genes as medicines in the therapy of genetic and hereditary diseases. In gene therapy a flawed gene can be replaced in order to eliminate the genetic cause of a disease. In this specific therapy, some times cells may be removed from the patient in order to differentiate them and halt the genetic cause of the disease.

Companies that first invested in the development of pharmaceutical biotechnology were flexible US companies that exploited the related research in order to develop medicines for chronic and rare diseases. These companies, such as Amgen and Biogen, are the first generation of developers of biotechnology-derived medicines, and as a part of the new economy, they were the cornerstone of the financial economy of the US over the last decade.